Can CJC-1295 be stacked with ipamorelin?
Yes — the CJC-1295 No DAC + ipamorelin combination engages two distinct G-protein-coupled receptors on the same pituitary somatotroph cells simultaneously. CJC-1295 No DAC binds the GHRH receptor; ipamorelin binds the growth hormone secretagogue receptor (GHSR-1a, the ghrelin receptor). The dual-receptor engagement produces additive — and possibly synergistic — effects on pituitary GH release.
What the research literature says
The mechanistic rationale for the combination derives from independent characterisation of each component. The original Raun ipamorelin paper established the compound as a selective ghrelin-receptor agonist with discrete GH-pulse pharmacology (PMID 9849822). The Jetté CJC-1295 identification paper established the GHRH-analog class as long-acting GRF-receptor agonists; the No DAC variant retains the GHRH-receptor binding with shorter half-life (PMID 15817669). The Teichman clinical-pharmacology work documented prolonged GH and IGF-1 secretion under CJC-1295 stimulation (PMID 16352683).
The two pathways converge on the same pituitary somatotroph cell but engage independent receptor cascades. The GHRH receptor signals through Gαs / cAMP / PKA; the ghrelin receptor signals through Gαq / IP3 / DAG / calcium. The downstream convergence on GH-release machinery means dual-pathway engagement can produce additive responses without receptor cross-desensitisation in the way that two GHRH agonists or two ghrelin agonists would.
Published primary research on the specific CJC-1295 + ipamorelin combination is limited; most studies characterise the individual compounds. The mechanistic case for the combination derives from the independent receptor-pharmacology and the well-established principle of dual-pathway-agonism additivity in endocrine research.
Why this matters in research context
The Ronin catalog offers both single-compound vials and a combined-formulation single vial branded as the CJC-1295 + Ipamorelin Blend (5 mg + 5 mg fixed-ratio loadings). Researchers running protocols that specifically need the dual-receptor engagement can use either the blend (simpler reconstitution, fixed ratio) or the standalone vials (independent dose control of each component). The choice depends on whether the protocol’s experimental variables include the ratio between the two components.
Related compounds
- CJC-1295 No DAC 10mg — standalone single-component vial
- Ipamorelin 10mg — standalone single-component vial
- CJC-1295 + Ipamorelin Blend 10mg — single-vial combined formulation at fixed 5 + 5 mg loadings
Related research questions
- What is the half-life of CJC-1295 No DAC?
- What is the half-life of ipamorelin?
- What is the half-life of tesamorelin?
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.